Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients.
biomarker
colorectal cancer
glypican-4
prognosis
proteoglycans
shedding
syndecan-1 (SDC1)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
09
2022
accepted:
10
10
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
11
11
2022
Statut:
epublish
Résumé
Cell surface syndecans and glypicans play important roles in the development and prognosis of colorectal cancer (CRC). Their soluble forms from proteoglycan shedding can be detected in blood and have been proposed as new prognostic biomarkers in several cancer entities. However, studies on circulating syndecan-1 (SDC1) and glypican-4 (GPC4) in CRC are limited. We, therefore, evaluated the impact of plasma SDC1 and GPC4 on the prognosis of metastatic (m)CRC patients. The present study included 93 patients with mCRC. The endpoints were progression-free survival (PFS) and overall survival (OS) at 12 months. SDC1 and GPC4 levels were measured in plasma using enzyme-linked immunosorbent assays. Plasma levels of SDC1 and GPC4 were significantly correlated. Significant correlations of these two markers were also found with carcinoembryonic antigen (CEA). Kaplan-Meier curve analyses indicated that PFS and OS probabilities significantly decreased with increasing levels of SDC1 and GPC4, respectively. Multivariable Cox regression analyses showed that both markers were significantly associated with PFS and OS independently from clinicopathological characteristics including CEA. Respective adjusted hazard ratios (HR) together with corresponding 95% confidence intervals for one standard deviation change of SDC1 were 1.32 [1.02-1.84] for PFS and 1.48 [1.01-2.15] for OS. Adjusted HRs [95% confidence intervals] of GPC4 were 1.42 [1.07-1.89] for PFS and 2.40 [1.51-3.81] for OS. Results from area under the receiver operating characteristic curve analyses suggest that GPC4 and SDC1 add additional prognostic values to CEA for OS. In conclusion, we showed significant associations of circulating SDC1 and GPC4 with poor survival of mCRC patients.
Identifiants
pubmed: 36353562
doi: 10.3389/fonc.2022.1045995
pmc: PMC9638102
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1045995Informations de copyright
Copyright © 2022 Muendlein, Severgnini, Decker, Heinzle, Leiherer, Geiger, Drexel, Winder, Reimann, Mayer, Nonnenbroich and Dechow.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Dis Markers. 2019 Apr 30;2019:3768708
pubmed: 31182980
Atherosclerosis. 2022 Mar;345:33-38
pubmed: 35202959
Anal Cell Pathol (Amst). 2018 Jun 20;2018:8389595
pubmed: 30027065
Cancer Res. 2002 Sep 15;62(18):5210-7
pubmed: 12234986
Diagnostics (Basel). 2020 Oct 23;10(11):
pubmed: 33114033
Recent Pat Biotechnol. 2018;12(4):269-279
pubmed: 30062978
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
J Clin Endocrinol Metab. 2014 Dec;99(12):E2697-701
pubmed: 25144630
eNeuro. 2021 Aug 9;8(4):
pubmed: 34301723
Cancer Med. 2020 Jan;9(1):361-373
pubmed: 31693304
Intensive Care Med Exp. 2019 Jan 7;7(1):2
pubmed: 30618011
Pathol Res Pract. 2019 Oct;215(10):152612
pubmed: 31474314
Biology (Basel). 2021 Jun 11;10(6):
pubmed: 34208075
Mol Biol Rep. 2012 May;39(5):5465-71
pubmed: 22179693
Dis Markers. 2015;2015:796052
pubmed: 26420915
Annu Rev Biochem. 1999;68:729-77
pubmed: 10872465
Oncol Rep. 2005 Oct;14(4):925-32
pubmed: 16142353
Front Oncol. 2021 Nov 11;11:778752
pubmed: 34858858
Pak J Med Sci. 2021 Jan-Feb;37(1):114-120
pubmed: 33437261
Blood. 2010 Mar 25;115(12):2449-57
pubmed: 20097882
Mol Cell Biol. 2004 Oct;24(19):8745-52
pubmed: 15367691
Int J Cardiol. 2022 Dec 15;369:54-59
pubmed: 35944770
J Clin Endocrinol Metab. 2013 Jul;98(7):2897-901
pubmed: 23633195
Front Cell Dev Biol. 2022 Jan 18;9:784983
pubmed: 35118073
Ther Adv Med Oncol. 2022 Jan 19;14:17588359211072703
pubmed: 35237350
Korean J Intern Med. 2018 Mar;33(2):367-382
pubmed: 27809453
Anticancer Res. 2012 Sep;32(9):3977-85
pubmed: 22993347
BMC Gastroenterol. 2015 Oct 30;15:152
pubmed: 26518017
J Endocrinol Invest. 2021 Apr;44(4):781-790
pubmed: 32816247
Biochem J. 2008 Mar 15;410(3):503-11
pubmed: 17967162
Int J Cancer. 2013 May 1;132(9):2157-63
pubmed: 23015513
Cancers (Basel). 2022 Feb 20;14(4):
pubmed: 35205811
Cell Tissue Res. 2016 Sep;365(3):643-55
pubmed: 27365088
Int J Cancer. 2016 Nov 15;139(10):2325-35
pubmed: 27472156
Prostate. 2016 Aug;76(11):977-85
pubmed: 27062540
Sci Rep. 2022 Jun 17;12(1):10168
pubmed: 35715556
Acta Diabetol. 2014 Dec;51(6):981-90
pubmed: 25240528
Diabetes. 2012 Sep;61(9):2289-98
pubmed: 22751693
Br J Cancer. 2014 Nov 11;111(10):1965-76
pubmed: 25321193
PLoS One. 2017 Nov 15;12(11):e0188139
pubmed: 29141049
Lung Cancer. 2003 Aug;41(2):171-7
pubmed: 12871780
Sci Rep. 2021 Feb 22;11(1):4287
pubmed: 33619304
World J Gastrointest Oncol. 2021 Nov 15;13(11):1551-1560
pubmed: 34853636
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Urol Oncol. 2018 Jun;36(6):312.e9-312.e15
pubmed: 29628317
J Cell Biochem. 2018 Nov;119(11):9498-9512
pubmed: 30010221
Semin Thromb Hemost. 2021 Apr;47(3):295-307
pubmed: 33794553
Blood. 2000 Jan 15;95(2):388-92
pubmed: 10627439
Development. 2015 May 15;142(10):1767-76
pubmed: 25968312
Dev Dyn. 2003 Jun;227(2):170-84
pubmed: 12761845